Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
252.64
0.00 (0.00%)
May 12, 2025, 4:00 PM - Market closed
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Bio-Rad Laboratories stock ranges from a low of $270 to a high of $392. The average price target of $330.5 forecasts a 30.82% increase in the stock price over the next year.
Price Target: $330.50 (+30.82%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
UBS | UBS | Strong Buy Maintains $355 → $310 | Strong Buy | Maintains | $355 → $310 | +22.71% | May 2, 2025 |
Citigroup | Citigroup | Strong Buy Maintains $400 → $350 | Strong Buy | Maintains | $400 → $350 | +38.54% | May 2, 2025 |
RBC Capital | RBC Capital | Buy Maintains $409 → $392 | Buy | Maintains | $409 → $392 | +55.16% | May 2, 2025 |
Wells Fargo | Wells Fargo | Hold Maintains $320 → $270 | Hold | Maintains | $320 → $270 | +6.87% | Apr 17, 2025 |
Wells Fargo | Wells Fargo | Hold Maintains $360 → $345 | Hold | Maintains | $360 → $345 | +36.56% | Feb 12, 2025 |
Financial Forecast
Revenue This Year
2.55B
from 2.57B
Decreased by -0.53%
Revenue Next Year
2.66B
from 2.55B
Increased by 4.35%
EPS This Year
9.73
from -65.36
EPS Next Year
11.34
from 9.73
Increased by 16.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 2.7B | 2.9B | 3.0B | |
Avg | 2.6B | 2.7B | 2.8B | |
Low | 2.4B | 2.5B | 2.6B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 4.1% | 12.4% | 12.3% | |
Avg | -0.5% | 4.3% | 3.9% | |
Low | -4.7% | -2.0% | -3.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 10.76 | 12.76 | 14.18 | |
Avg | 9.73 | 11.34 | 12.21 | |
Low | 8.43 | 9.21 | 10.17 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | - | 31.1% | 25.0% | |
Avg | - | 16.5% | 7.7% | |
Low | - | -5.4% | -10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.